SIBO/FIBO, FODMAP Fermentation, Histamine Intolerance, Meal Storage Dynamics, and Gut–Brain Axis Immunology: A Systems Neuroimmune Review (2020–2026)- Deep Dive- Sarah Fowler

Abstract 

Functional gastrointestinal disorders (FGIDs), particularly irritable bowel syndrome (IBS), are increasingly understood as disorders of gut–brain–immune interaction. Emerging evidence implicates small intestinal bacterial overgrowth (SIBO), fermentative intestinal bacterial overgrowth (FIBO), FODMAP carbohydrate fermentation, and histamine metabolism in symptom generation. Importantly, post-cooking food storage (meal-prep histamine accumulation) represents an underrecognized exogenous histamine source that may amplify symptom severity. This review integrates recent literature (2020–2026) to construct a unified neuroimmune model linking microbial fermentation, mast cell activation, histamine signaling, and gut–brain axis dysfunction. We propose that symptom expression arises from nonlinear interactions between dietary substrates, microbial ecology, immune activation, and neural amplification pathways rather than isolated triggers.

Subject Terms 

SIBO; Small Intestinal Bacterial Overgrowth; FIBO; Fermentative Dysbiosis; Irritable Bowel Syndrome; IBS; FODMAP; Fermentable Carbohydrates; Intestinal Fermentation; Gut Microbiota; Dysbiosis; Histamine Intolerance; Biogenic Amines; Histamine Metabolism; Diamine Oxidase (DAO); Mast Cells; Mast Cell Activation Syndrome; MCAS; Gut–Brain Axis; Neurogastroenterology; Neuroimmune Signaling; Intestinal Permeability; Leaky Gut; Vagal Nerve Signaling; Visceral Hypersensitivity; Gastrointestinal Inflammation; Microbial Metabolites; Short-Chain Fatty Acids; Food Storage Histamine; Meal Prep; Food Biogenic Amine Accumulation; Immune Activation; Mucosal Immunity; Functional Gastrointestinal Disorders; FGIDs; Motility Disorders; Migrating Motor Complex; MMC Dysfunction; Diet Therapy; Elimination Diets; Low FODMAP Diet; Personalized Nutrition; Systems Biology; Microbiome–Immune Interaction; Psychoneuroimmunology; Postprandial Symptoms; Food Sensitivity; Gut–Brain–Immune Axis

Introduction 

Functional gastrointestinal symptoms are increasingly viewed as disorders of gut–brain interaction involving immune, microbial, and neural pathways. SIBO and FIBO represent dysbiosis states characterized by abnormal fermentation in the small intestine and altered microbial metabolism. FODMAPs act as primary fermentable substrates, while histamine functions as a key immunomodulatory mediator linking microbial activity and host immune responses. Recent literature suggests that mast cell activation and gut–brain axis dysfunction amplify symptom severity beyond mechanical distension alone (Cryan et al., 2022; Camilleri & Boeckxstaens, 2023). However, clinical models rarely integrate dietary timing (meal storage), fermentation biology, and immune signaling into a unified framework. This review addresses this gap.

Methods (Systematic Narrative Approach)

A structured narrative systematic review was conducted using peer-reviewed literature (2020–2026) across gastroenterology, immunology, microbiology, and nutritional science domains. Search themes included SIBO, FODMAP fermentation, histamine intolerance, mast cell activation, gut–brain axis signaling, and food histamine formation. Inclusion criteria prioritized mechanistic and clinical studies relevant to functional gastrointestinal disorders. Studies addressing microbial metabolism, dietary fermentation, and immune signaling were synthesized into an integrated model.

SIBO/FIBO As Fermentation- Immune Dysbiosis 

SIBO is characterized by abnormal bacterial proliferation in the small intestine, while FIBO reflects broader fermentative imbalance. These conditions result from impaired motility, altered bile acid metabolism, and microbial ecological disruption. Gas production (hydrogen, methane, CO₂) contributes to bloating and motility disturbances. Importantly, dysbiosis also shifts microbial enzymatic pathways toward biogenic amine production, including histamine. This positions SIBO/FIBO as both a metabolic and immune-modulating disorder.

Table 1: Pathophysiological Features of SIBO/ FIBO 

Domain	Mechanism	Clinical Effect
Motility dysfunction	Impaired MMC activity	Bacterial overgrowth
Fermentation	Gas production (H₂, CH₄)	Bloating, pain
Microbial shift	Dysbiosis	Reduced diversity
Immune activation	Barrier disruption	Hypersensitivity
Biogenic amines	Histamine production	Neuroimmune symptoms

FODMAP Fermentation and Luminal Distension 

FODMAP carbohydrates are poorly absorbed and rapidly fermented by intestinal microbiota. This leads to osmotic shifts and gas production, resulting in abdominal distension and pain. Clinical evidence supports symptom improvement following low-FODMAP interventions in IBS populations (Black et al., 2022). However, prolonged restriction may reduce beneficial taxa such as Bifidobacteria and impair short-chain fatty acid production, which are important for immune regulation.

Table 2: FODMAP Effects on Gut Physiology 

Process	Mechanism	Outcome
Fermentation	Bacterial metabolism	Gas production
Osmotic load	Poor absorption	Diarrhea
Distension	Luminal pressure	Pain signaling
Microbiome shift	Reduced fiber diversity	Immune dysregulation

Histamine Metabolism Microbial and Host Systems 

Histamine is produced endogenously by mast cells and exogenously by gut bacteria via histidine decarboxylase activity. Dysbiosis increases microbial histamine production, contributing to immune activation and visceral hypersensitivity. Histamine acts on H1–H4 receptors, influencing vascular, neural, and immune systems (Huang et al., 2023). Impaired degradation via diamine oxidase (DAO) further exacerbates systemic accumulation.

Meal Storage and Post- Cooking Histamine Accumulation 

A critical but underrecognized exposure pathway is histamine accumulation in stored foods. Protein-rich foods undergo bacterial decarboxylation during refrigeration, increasing histamine content over time. EFSA reports indicate significant histamine elevation within 24–72 hours depending on storage conditions (EFSA, 2023). This introduces a dynamic environmental trigger in addition to endogenous microbial production.

Table 3: Histamine Sources and Amplifiers 

Source	Mechanism	Risk Level
Fresh food	Low histamine	Low
Refrigerated protein (24–48h)	Bacterial decarboxylation	Moderate
Aged/fermented foods	High histamine load	High
SIBO dysbiosis	Endogenous production	High
DAO deficiency	Impaired breakdown	Amplifier

 

Mast Cell Activation and Immune Signal Integration 

Mast cells serve as immune integration hubs in the gut mucosa. They are activated by microbial metabolites, histamine, and dietary antigens. Activation leads to release of histamine, cytokines, and proteases, increasing epithelial permeability and nociceptor sensitization (Wouters et al., 2022). This establishes a feed-forward loop between microbial dysbiosis and immune hypersensitivity.

Table 4: Mast Cell Mediator Effects 

Mediator	Target	Effect
Histamine	Smooth muscle	Spasm, pain
Tryptase	Epithelium	Barrier disruption
Cytokines	Immune system	Inflammation
Prostaglandins	Nerves	Pain amplification

Gut-Brain Axis Neuroimmune Signaling 

The gut–brain axis integrates immune, endocrine, and neural communication. Microbial metabolites such as histamine and lipopolysaccharides activate vagal and systemic immune pathways. These signals influence central nervous system processing, contributing to anxiety, fatigue, and cognitive dysfunction (Cryan et al., 2022). Histamine also acts as a neuromodulator in brain regions regulating arousal and emotion.

Integrated Neuroimmune Model 

A unified model emerges in which:

• FODMAPs → fermentation substrate
• SIBO/FIBO → microbial overgrowth engine
• Histamine → immune + neural amplifier
• Meal storage → external histamine exposure
• Mast cells → immune integration node
• Gut–brain axis → symptom output system

These elements form a nonlinear feedback loop rather than independent pathways.

Table 5: Integrated Systems Model 

Layer	Function	Clinical Outcome
Diet	FODMAP input	Fermentation load
Microbiome	SIBO/FIBO	Gas + histamine
Immune system	Mast cells	Inflammation
Barrier	Permeability	Sensitization
Brain	CNS processing	Anxiety, brain fog
Environment	Meal storage	Histamine amplification

Clinical Implications 

Management requires multi-layer intervention:

1. Short-term FODMAP reduction (fermentation control)
2. Histamine load reduction (diet + storage timing)
3. Motility restoration (MMC support)
4. Microbiome modulation (targeted therapy)
5. Mast cell stabilization (immune control)
6. Gut–brain axis regulation (stress + vagal tone)

Single-domain interventions are insufficient due to system redundancy and feedback loops.

Conclusion 

SIBO/FIBO, FODMAP fermentation, histamine metabolism, meal storage dynamics, and gut–brain axis signaling form an integrated neuroimmune system governing functional gastrointestinal symptoms. Histamine serves as a central amplifier linking microbial and dietary triggers to immune and neural outputs. Meal-prep practices represent a clinically significant and modifiable environmental factor. Future research should adopt systems immunology approaches integrating microbiome, immune, and neurophysiological data.

References

Black, C. J., et al. (2022). Low FODMAP diet efficacy in IBS. Gut, 71(6), 1117–1126.
Camilleri, M., & Boeckxstaens, G. (2023). IBS pathophysiology. Gut, 72(4), 590–599.
Cryan, J. F., et al. (2022). Microbiota–gut–brain axis. Physiological Reviews, 102(4), 1871–1909.
EFSA. (2023). Histamine in food risk assessment. EFSA Journal, 21(6).
Huang, H., et al. (2023). Histamine intolerance mechanisms. Nutrients, 15(4), 876.
Staudacher, H. M., & Gibson, P. R. (2022). Low FODMAP mechanisms. Curr Opin Gastroenterol.
Wang, L., et al. (2022). Microbiota-derived histamine. Frontiers in Immunology, 13, 845312.
Wouters, M. M., et al. (2022). Mast cells in GI disorders. Clin Gastroenterol Hepatol.
Bogielski, P., et al. (2024). SIBO and psychiatric comorbidity. PubMed Central.
Chu, P., et al. (2025). Microbiome shifts in restrictive diets. J Food Sci.
Ford, A. C., et al. (2020). IBS clinical overview. Lancet.
Simrén, M., & Tack, J. (2021). Gut–brain interaction in IBS. Nat Rev Gastroenterol Hepatol.
Major, G., et al. (2022). Fermentation and IBS symptoms. Gastroenterology.
Shah, A., et al. (2024). SIBO motility mechanisms. Nutrition.
Wu, J., et al. (2022). Gut–brain axis and IBS symptoms. Aliment Pharmacol Ther.
Sánchez-Pérez, A., et al. (2023). Mast cell neuroimmune signaling. Front Immunol.
Zhao, L., et al. (2024). Microbial metabolites and immune signaling. Cell Host Microbe.
Kim, M., et al. (2023). Histamine and gut inflammation. Nutrients.